Vlado Perkovic's Publications

• EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IGAN STUDY

  Conference Papers

  2024

  AMERICAN JOURNAL OF KIDNEY DISEASES

• Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study

  Journal articles

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• SPARSENTAN (SPAR) SHOWS CLINICALLY MEANINGFUL TREATMENT EFFECTS VS IRBESARTAN (IRB) IN PATIENTS WITH IGA NEPHROPATHY (IGAN) IN THE PHASE 3 PROTECT TRIAL

  Conference Papers

  2024

  AMERICAN JOURNAL OF KIDNEY DISEASES

• Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Results of an International Randomized Controlled Trial (PEXIVAS)

  Journal articles

  2024

  American Journal of Respiratory and Critical Care Medicine

• Combination Treatment with Verinurad and Allopurinol in CKD: A Randomized Placebo and Active Controlled Trial

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Daprodustat and Heart Failure in CKD

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

  Journal articles

  2024

  Kidney International Reports

• The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

  Journal articles

  2024

  NEPHROLOGY DIALYSIS TRANSPLANTATION

• Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

  Journal articles

  2024

  Diabetes Care

• VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

  Journal articles

  2024

  Journal of the American Society of Nephrology

• Barriers to Care: New Medications and CKD

  Journal articles

  2024

  Kidney International Reports

• Targeting APRIL in the Treatment of IgA Nephropathy

  Journal articles

  2024

  Clinical Journal of the American Society of Nephrology

• Kidney Function, Albuminuria, and Risk of Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis

  Journal articles

  2024

  American Journal of Kidney Diseases

• Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin A Secondary Analysis of Randomized Clinical Trials

  Journal articles

  2024

  JAMA Cardiology

• Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

  Journal articles

  2024

  Journal of the American Heart Association

• Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

  Journal articles

  2024

  Circulation

• Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data

  Journal articles

  2024

  The Lancet Regional Health - Western Pacific

• The Prevalence of CKD in Australian Primary Care: Analysis of a National General Practice Dataset

  Journal articles

  2024

  Kidney International Reports

• Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial

  Journal articles

  2024

  Diabetes, Obesity and Metabolism

• Effects of Semaglutide on CKD in Patients With Type 2 Diabetes

  Journal articles

  2024

  Kidney International Reports

• Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE)

  Journal articles

  2024

  Journal of the American Society of Nephrology

• The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system

  Journal articles

  2024

  Peritoneal Dialysis International

• Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy

  Journal articles

  2024

  Kidney International

• Combination therapy with kidney protective therapies: Optimizing the benefits?

  Journal articles

  2024

  Current Opinion in Nephrology and Hypertension

• ALBUMINURIA, KIDNEY FUNCTION AND HEART FAILURE IN TYPE 2 DIABETES: A SECONDARY ANALYSIS FROM THE CANVAS PROGRAM AND CREDENCE TRIAL

  Conference Papers

  2024

  NEPHROLOGY

• Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mLmin: Phase 3 APPLAUSE-IgAN Subcohort Results

  Journal articles

  2024

  Journal of the American Society of Nephrology